Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Forty Seven Inc.
Sort By
Newest First
Sign in
1 / 1
1 / 1
M&A
Gilead to Acquire Forty Seven for $4.9 Billion
Gilead Sciences
PR-M03-20-NI-003
Mar 02, 2020
Strategic Collaboration
Forty Seven Inc. to Collaborate on a Novel Immuno-Oncology Combination for Leukemia and Bladder Cancer
Forty Seven Inc.
PR-M01-18-NI-043
Jan 16, 2018
Immuno-Oncology
Forty Seven Inc. to Collaborate with Merck KGaA, Darmstadt, Germany, on a Novel Immuno-Oncology Combination for Ovarian Cancer
Forty Seven Inc.
PR-M01-18-NI-042
Jan 16, 2018
